The selectivity of protein kinase inhibitors: A further update

Biochemical Journal

Volumn 408, Issue 3, 2007, Pages 297-315

  Bain, Jenny ^a   Plater, Lorna ^a   Elliott, Matt ^a   Shpiro, Natalia ^a   Hastie, C James ^a   Mclauchlan, Hilary ^a   Klevernic, Iva ^a   Arthur, J Simon C ^a   Alessi, Dario R ^a   Cohen, Philip ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Anti cancer drugs; Drug discovery; Inhibitor specificity; Kinase profiling; Protein kinase

Indexed keywords

ANTI CANCER DRUGS; DRUG DISCOVERY; INHIBITOR SPECIFICITY; KINASE PROFILING; PHOSPHATIDYLINOSITOL; PROTEIN KINASES; RAPAMYCIN;

ALCOHOLS; CELLS; DRUG PRODUCTS; PROTEINS;

ENZYME INHIBITION;

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ALSTERPAULLONE; BIRB 0796; BIRD 0796; BX 320; BX 795; CT 99021; KENPAULLONE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; PROTEIN KINASE INHIBITOR; PURVALANOL A; RAPAMYCIN; ROSCOVITINE; SL 0101; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME PURIFICATION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; DRUG DESIGN; ENZYME ACTIVATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECOMBINANT PROTEINS; SPODOPTERA;

MAMMALIA; RAPTORES;

EID: 36549040859     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20070797     Document Type: Article

References (99)

1. Davies, S. P., Reddy, H., Caivano, M. and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105
2. Bain, J., McLauchlan, H., Elliott, M. and Cohen, P. (2003) The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199-204
3. Regan, J., Breitfelder, S., Cirillo, P., Gilmore, T., Graham, A. G., Hickey, E., Klaus, B., Madwed, J., Moriak, M., Moss, N. et al. (2002) Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 45, 2994-3008
4. Shpiro, N. A. and Marquez, R. (2005) PD-184352. Synth. Commun. 35, 2265-2270
5. Barrett, S. D., Biwersi, C., Kaufman, M., Tecle, H. and Warmus, J. S. (2002) Preparation of oxygenated esters of 4-iodophenylaminobenzhydroxyamic acids as MEK inhibitors, World Pat. WO/2002/006213
6. Nuss, J. M., Harrison, S. D., Ring, D. B., Boyce, R. S., Brown, S. P., Goff, D., Johnson, K., Pfister, K. B., Ramurthy, S., Renhowe, P. A. et al. (1999) Preparation of aminopyrimidines and pyridines as glycogen synthase kinase 3 inhibitors. World Pat. WO/1999/065897
7. Hoffmann, M., Grauert, M., Breitfelder, S., Eickmeier, C., Pohl, G., Lehmann-Lintz, T., Redemann, N., Schnapp, G., Steegmaier, M., Bauer, E. and Quant, J. J. (2003) Preparation of dihydropteridinones as cell proliferation inhibitors. World Pat. WO/2003/020722
8. Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormo, M., Nilsson, Y., Radesater, A. C., Jerning, E., Markgren, P. O., Borgegard, T. et al. (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278, 45937-45945
9. Hayakawa, M., Kaizawa, H., Moritomo, H., Kawaguchi, K.-I., Koizumi, T., Yamano, M., Matsuda, K., Okada, M. and Ohta, M. (2001) Preparation of condensed heteroaryl derivatives as phosphatidylinositol 3-kinase inhibitors and anticancer agents. World Pat. WO/2001/083456
10. Beck, J. R. (1972) Direct synthesis of benzo[b]thiophene-2- carboxylate esters involving nitro displacement. J. Org. Chem. 37, 3224-3226
11. Arnautu, A., Collot, V., Ros, J. C., Alayrac, C., Witulski, B. and Rault, S. (2002) Sonogashira cross coupling reaction of 3-iodoindazoles with various terminal alkynes: a mild and flexible strategy to design 2-azatryptamines. Tetrahedron Lett. 43, 2695-2697
12. Voisin, A. S., Bouillon, A., Lancelot, J. C. and Rault, S. (2005) Efficient synthesis of halohydroxypyridines by hydroxydeboronation. Tetrahedron 61, 1417-1421
13. Li, Q., Woods, K. W., Zhiu, G. D., Fischer, J. P., Gong, J., Li, T., Gandhi, V., Thomas, S. A., Packard, G., Song, X. et al. (2003) Preparation of pyrimidine derivatives as protein kinases inhibitors. World Pat. WO/2003/051366
14. Burgess, J. L. and Callahan, J. F. (2000) Preparation of triarylimidazoles as activin-like kinase (ALK)-5 receptor modulators. World Pat. WO/2000/061576
15. Liverton, N. J., Butcher, J. W., Claiborne, C. F., Claremon, D. A., Libby, B. E., Nguyen, K. T., Pitzenberger, S. M., Selnick, H. G., Smith, G. R., Tebben, A. et al. (1999) Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 42, 2180-2190
16. Callahan, J. F., Burgess, J. L., Fornwald, J. A., Gaster, L. M., Harling, J. D., Harrington, F. P., Heer, J., Kwon, C., Lehr, R., Mathur, A. et al. (2002) Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5). J. Med. Chem. 45, 999-1001
17. Charrier, J.-D., Mazzei, F., Kay, D. and Miller, A. (2004) Processes for preparing 6-pyrazolylpyrimidine as inhibitors of protein kinases, in particular Aurora kinases, by nucleophilic substitution, World Pat. WO/2004/000833
18. Treiber, H.-J., Behl, B. and Hofmann, H. P. (1994) Preparation of 4-oxoimidazolo[1.2-a]quinoxalines as antagonists of excitatory amino acids. German Pat. DE 4329970
19. Tominaga, Y., Honkawa, Y., Hara, M. and Hosomi, A. (1990) Synthesis of pyrazolo[3,4-D]pyrimidine derivatives using ketene dithioacetate. J. Heterocyclic Chem. 27, 775-783
20. Bryant, J., Kochanny, M. J., Yuan, S., Khim, S. K., Buckman, B., Arnaiz, D., Boemer, U., Briem, H., Esperling, P., Huwe, P. et al. (2004) Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents, World Pat. WO/2004/048343
21. Sun, L., Tran, N., Liang, C., Tang, F., Rice, A., Schreck, R., Waltz, K., Shawver, L. K., McMahon, G. and Tang, C. (1999) Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl] indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem. 42, 5120-5130
22. Alessi, D. R., Cohen, P., Ashworth, A., Cowley, S., Leevers, S. J. and Marshall, C. J. (1995) Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Methods Enzymol. 255, 279-290
23. Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R. and Lee, J. C. (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364, 229-233
24. Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P., Blencke, S., Gutbrod, H., Salassidis, K., Stein-Gerlach, M., Missio, A., Cotten, M. and Daub, H. (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A 100, 15434-15439
25. Hall-Jackson, C. A., Goedert, M., Hedge, P. and Cohen, P. (1999) Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 18, 2047-2054
26. Fryer, L. G., Parbu-Patel, A. and Carling, D. (2002) Protein kinase inhibitors block the stimulation of the AMP-activated protein kinase by 5-amino-4-imidazolecarboxamide riboside. FEBS Lett. 531, 189-192
27. Eyers, P. A., van den IJssel, P., Quinlan, R. A., Goedert, M. and Cohen, P. (1999) Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett. 451, 191-196
28. Cheung, P. C., Campbell, D. G., Nebreda, A. R. and Cohen, P. (2003) Feedback control of the protein kinase TAK1 by SAPK2a/p38α. EMBO J. 22, 5793-5805
29. Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S. and Regan, J. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9, 268-272
30. Kuma, Y., Sabio, G., Bain, J., Shpiro, N., Marquez, R. and Cuenda, A. (2005) BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem. 280, 19472-19479
31. Jaeschke, A., Karasarides, M., Ventura, J. J., Ehrhardt, A., Zhang, C., Flavell, R. A., Shokat, K. M. and Davis, R. J. (2006) JNK2 is a positive regulator of the cJun transcription factor. Mol. Cell 23, 899-911
32. Ventura, J. J., Hubner, A., Zhang, C., Flavell, R. A., Shokat, K. M. and Davis, R. J. (2006) Chemical genetic analysis of the time course of signal transduction by JNK. Mol. Cell 21, 701-710
33. Blake, R. A., Broome, M. A., Liu, X., Wu, J., Gishizky, M., Sun, L. and Courtneidge, S. A. (2000) SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell Biol. 20, 9018-9027
34. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A. and Connelly, P. A. (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271, 695-701
35. Liu, Y., Bishop, A., Witucki, L., Kraybill, B., Shimizu, E., Tsien, J., Ubersax, J., Blethrow, J., Morgan, D. O. and Shokat, K. M. (1999) Structural basis for selective inhibition of Src family kinases by PP1. Chem. Biol. 6, 671-678
36. Windheim, M., Lang, C., Peggie, M., Cummings, L. A. and Cohen, P. (2007) Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochem. J. 404, 179-190
37. Eyers, P. A., Craxton, M., Morrice, N., Cohen, P. and Goedert, M. (1998) Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol. 5, 321-328
38. Gum, R. J., McLaughlin, M. M., Kumar, S., Wang, Z., Bower, M. J., Lee, J. C., Adams, J. L., Livi, G. P., Goldsmith, E. J. and Young, P. R. (1998) Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J. Biol. Chem. 273, 15605-15610
39. Bishop, A. C., Ubersax, J. A., Petsch, D. T., Matheos, D. P., Gray, N. S., Blethrow, J., Shimizu, E., Tsien, J. Z., Schultz, P. G., Rose, M. D. et al. (2000) A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407, 395-401
40. Wiggin, G. R., Soloaga, A., Foster, J. M., Murray-Tait, V., Cohen, P. and Arthur, J. S. (2002) MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol. Cell Biol. 22, 2871-2881
41. Shaw, M. and Cohen, P. (1999) Role of protein kinase B and the MAP kinase cascade in mediating the EGF-dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells. FEBS Lett. 461, 120-124
42. Hall-Jackson, C. A., Eyers, P. A., Cohen, P., Goedert, M., Boyle, F. T., Hewitt, N., Plant, H. and Hedge, P. (1999) Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559-568
43. Lyons, J. F., Wilhelm, S., Hibner, B. and Bollag, G. (2001) Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 8, 219-225
44. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M. et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109
45. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T. and Saltiel, A. R. (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494
46. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F. et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623-18632
47. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Van Becelaere, K., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S. et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5, 810-816
48. Reference deleted
49. Kamakura, S., Moriguchi, T. and Nishida, E. (1999) Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem .274, 26563-26571
50. Mody, N., Leitch, J., Armstrong, C., Dixon, J. and Cohen, P. (2001) Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. 502, 21-24
51. Sapkota, G. P., Cummings, L., Newell, F. S., Armstrong, C., Bain, J., Frodin, M., Grauert, M., Hoffmann, M., Schnapp, G., Steegmaier, M. et al. (2007) BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem. J. 401, 29-38
52. Smith, J. A., Poteet-Smith, C. E., Xu, Y., Errington, T. M., Hecht, S. M. and Lannigan, D. A. (2005) Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 65, 1027-1034
53. Cohen, M. S., Zhang, C., Shokat, K. M. and Taunton, J. (2005) Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318-1321
54. Zaru, R., Ronkina, N., Gaestel, M., Arthur, J. S. C. and Watts, C. (2007) The MAP kinase-activated Rsk controls an acute Toll-like receptor signalling response in dendritic cells and is activated via two distinct pathways. Nat. Immunol. 8, 1227-1235
55. Cohen, M. S., Hadjivassiliou, H. and Taunton, J. (2007) A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat. Chem. Biol. 3, 156-160
56. Cohen, P. and Goedert, M. (2004) GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 3, 479-487
57. Murray, J. T., Campbell, D. G., Morrice, N., Auld, G. C., Shpiro, N., Marquez, R., Peggie, M., Bain, J., Bloomberg, G. B., Grahammer, F. et al. (2004) Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem. J. 384, 477-488
58. Nakanishi, S., Kakita, S., Takahashi, I., Kawahara, K., Tsukuda, E., Sano, T., Yamada, K., Yoshida, M., Kase, H., Matsuda, Y. et al. (1992) Wortmannin, a microbial product inhibitor of myosin light chain kinase. J. Biol. Chem. 267, 2157-2163
59. Liu, Y., Shreder, K. R., Gai, W., Corral, S., Ferris, D. K. and Rosenblum, J. S. (2005) Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol. 12, 99-107
60. Gharbi, S. I., Zvelebil, M. J., Shuttleworth, S. J., Hancox, T., Saghir, N., Timms, J. F. and Waterfield, M. D. (2007) Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 404, 15-21
61. Workman, P., Raynaud, F., Clarke, P., te Poele, R., Eccles, S., Kelland, L., Di Stefano, F., Ahmadi, K., Parker, P. and Waterfield, M. D. (2004) Pharmacological properties and in vitro and in vivo antitumour activity of the potent and selective PI3 kinase inhibitor PI103. Eur. J. Cancer 40, 414A
62. Fan, Q. W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M. and Weiss, W. A. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341-349
63. Heitman, J., Movva, N. R. and Hall, M. N. (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905-909
64. Tyler, R. K., Shpiro, N., Marquez, R. and Eyers, P. A. (2007) VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle 6, in the press
65. +/- mice. Curr. Biol. 15, 1839-1846
66. Feldman, R. I., Wu, J. M., Polokoff, M. A., Kochanny, M. J., Dinter, H., Zhu, D., Biroc, S. L., Alicke, B., Bryant, J., Yuan, S. et al. (2005) Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J. Biol. Chem. 280, 19867-19874
67. Korherr, C., Gille, H., Schafer, R., Koenig-Hoffmann, K., Dixelius, J., Egland, K. A., Pastan, I. and Brinkmann, U. (2006) Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc. Natl. Acad. Sci. U.S.A. 103, 4240-4245
68. Chien, Y., Kim, S., Bumeister, R., Loo, Y. M., Kwon, S. W., Johnson, C. L., Balakireva, M. G., Romeo, Y., Kopelovich, L., Gale, Jr., M. et al. (2006) RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127, 157-170
69. Luo, Y., Shoemaker, A. R., Liu, X., Woods, K. W., Thomas, S. A., de Jong, R., Han, E. K., Li, T., Stoll, V. S., Powlas, J. A. et al. (2005) Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. 4, 977-986
70. Barnett, S. F., Defeo-Jones, D., Fu, S., Hancock, P. J., Haskell, K. M., Jones, R. E., Kahana, J. A., Kral, A. M., Leander, K., Lee, L. L. et al. (2005) Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385, 399-408
71. Logie, L., Ruiz-Alcaraz, A. J., Keane, M., Woods, Y. L., Bain, J., Marquez, R., Alessi, D. R. and Sutherland, C. (2007) Characterisation of a protein kinase B inhibitor in vitro and in insulin treated liver cells, Diabetes 56, 2218-2227
72. Rena, G., Bain, J., Elliott, M. and Cohen, P. (2004) D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 5, 60-65
73. Song, Y., Kesuma, D., Wang, J., Deng, Y., Duan, J., Wang, J. H. and Qi, R. Z. (2004) Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem. Biophys. Res. Commun. 317, 128-132
74. Altafaj, X., Dierssen, M., Baamonde, C., Marti, E., Visa, J., Guimera, J., Oset, M., Gonzalez, J. R., Florez, J., Fillat, C. and Estivill, X. (2001) Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 10, 1915-1923
75. Arron, J. R., Winslow, M. M., Polleri, A., Chang, C. P., Wu, H., Gao, X., Neilson, J. R., Chen, L., Heit, J. J., Kim, S. K. et al. (2006) NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595-600
76. Waki, H., Park, K. W., Mitro, N., Pei, L., Damoiseaux, R., Wilpitz, D. C., Reue, K., Saez, E. and Tontonoz, P. (2007) The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARγ expression. Cell Metab. 5, 357-370
77. Meijer, L., Borgne, A., Mulner, O., Chong, J. P., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J. G. and Moulinoux, J. P. (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243, 527-536
78. Gray, N. S., Wodicka, L., Thunnissen, A. M., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L. et al. (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538
79. Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L. and Jiang, T. (2005) Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280, 31208-31219
80. Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, 3rd, W. H., Edeen, P. T. et al. (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. U.S.A. 102, 11011-11016
81. Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A. et al. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 10, 262-267
82. Godl, K., Gruss, O. J., Eickhoff, J., Wissing, J., Blencke, S., Weber, M., Degen, H., Brehmer, D., Orfi, L., Horvath, Z. et al. (2005) Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res. 65, 6919-6926
83. Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G. and Hardie, D. G. (2005) Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2, 9-19
84. 2+ in T lymphocytes. J. Exp. Med. 203, 1665-1670
85. Cho, J., Melnick, M., Solidakis, G. P. and Tsichlis, P. N. (2005) Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced by lipopolysaccharide via an IκB kinase-β-dependent pathway and is required for Tpl2 activation by external signals. J. Biol. Chem. 280, 20442-20448
86. Stafford, M. J., Morrice, N. A., Peggie, M. W. and Cohen, P. (2006) Interleukin-1 stimulated activation of the COT catalytic subunit through the phosphorylation of Thr290 and Ser62. FEBS Lett. 580, 4010-4014
87. Gaillard, P., Jeanclaude-Etter, I., Ardissone, V., Arkinstall, S., Cambet, Y., Camps, M., Chabert, C., Church, D., Cirillo, R. and Gretener, D. (2005) Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J. Med. Chem. 48, 4596-4607
88. Knauf, U., Tschopp, C. and Gram, H. (2001) Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol. Cell Biol. 21, 5500-5511
89. Gschwendt, M., Muller, H. J., Kielbassa, K., Zang, R., Kittstein, W., Rincke, G. and Marks, F. (1994) Rottlerin, a novel protein kinase inhibitor. Biochem. Biophys. Res. Commun. 199, 93-98
90. Hidaka, H., Inagaki, M., Kawamoto, S. and Sasaki, Y. (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23, 5036-5041
91. Amano, M., Chihara, K., Nakamura, N., Kaneko, T., Matsuura, Y. and Kaibuchi, K. (1999) The COOH terminus of Rho-kinase negatively regulates rho-kinase activity. J. Biol. Chem. 274, 32418-32424
92. Niggli, V. (1999) Rho-kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration. FEBS Lett. 445, 69-72
93. Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M. and Narumiya, S. (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990-994
94. Tachibana, E., Harada, T., Shibuya, M., Saito, K., Takayasu, M., Suzuki, Y. and Yoshida, J. (1999) Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir. 141, 13-19
95. Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., Yamamori, B., Feng, J., Nakano, T., Okawa, K. et al. (1996) Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273, 245-248
96. Sahai, E., Ishizaki, T., Narumiya, S. and Treisman, R. (1999) Transformation mediated by RhoA requires activity of ROCK kinases. Curr. Biol. 9, 136-145
97. Itoh, K., Yoshioka, K., Akedo, H., Uehata, M., Ishizaki, T. and Narumiya, S. (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 5, 221-225
98. Son, Y. K., Park, W. S., Kim, S. J., Earm, Y. E., Kim, N., Youm, J. B., Warda, M., Kim, E. and Han, J. (2006) Direct inhibition of a PKA inhibitor, H-89 on KV channels in rabbit coronary arterial smooth muscle cells. Biochem. Biophys. Res. Commun. 341, 931-937
99. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B. and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289, 1938-1942